Background: Oral anticoagulant drugs are proven to prevent thromboembolism in patients with atrial fibrillation (AF). To date, HAS-BLED score is used to assess bleeding risk. This study was conducted to compare simplified HAS-BLED (sHAS-BLED) with conventional HAS-BLED (cHAS-BLED) scores.
| INTRODUC TI ON
Atrial fibrillation (AF) is a common cardiac arrhythmia in clinical practice. Stroke prevention is paramount importance in AF management.
To date, only oral anticoagulant drugs (OACs) are proven to prevent thromboembolism in those patients. 1 According to standard clinical practice guidelines recommend OACs should be prescribed in AF patients with non-sex CHA 2 DS 2 -VASc of 1 or more (score of ≥ 1 in a male or ≥2 in a female). [2] [3] [4] Vitamin-K antigonists (VKAs) especially warfarin are the most common oral anticoagulant drugs prescribed in those patients.
International normalized ratio (INR) is a laboratory test for assessing anticoagulation control. 5 Quality of anticoagulation control is measured by time in therapeutic range (TTR) using Rosendaal method. 6 Previous clinical trials have demonstrated that poor TTR is associated with adverse events including thromboembolism, bleeding, and/or mortality. 7 Several clinical trials have demonstrated the score of 3 or more could predict poor anticoagulation control. [10] [11] [12] [13] [14] Until now, standard clinical practice guidelines recommend the use of HAS-BLED score to predict bleeding risk in those patients. [2] [3] [4] Labile INR in those score is defined as poor TTR (eg, TTR less than 60%). 15 However, TTR is a cumbersome calculated problem in clinical practice. This study was conducted to simplify HAS-BLED score by using SAMe-TT 2 R 2 score of 3 or more as a substitute for labile INR and compared simplified HAS-BLED (sHAS-BLED) with conventional HAS-BLED (cHAS-BLED) scores.
| ME THODS
The present study was the retrospective observational study. AF HAS-BLED score is defined following 2010 ESC guidelines for the management of AF. 16 Because of target INR should be ≥70% ideally 3 , labile INR is defined as TTR less than 70% in HAS-BLED score in this study. TTR is calculated by using Rosendaal method. 6 Conventional HAS-BLED (cHAS-BLED) score used the TTR less than 70% as labile INR, while simplified HAS-BLED (sHAS-BLED) score used SAMe-TT 2 R 2 score of 3 or more as a substitute for labile INR. distribution is skewed. A P-value of .05 or less was considered the statistical significance. Table 1 . The distribution of patients in SAMe-TT 2 R 2 score was shown in Figure 1 .
| RE SULTS
The sHAS-BLED score was compared with cHAS-BLED score by using paired Student's t test. This study demonstrated no statistically significant difference between sHAS-BLED and cHAS-BLED scores (P = .08) ( Table 2 ).
The sHAS-BLED score was analyzed by using Pearson's correlation relative to cHAS-BLED score. The sHAS-BLED and cHAS-BLED scores had a very strong correlation with a correlation coefficient of .86 (P < .01) ( Figure 2) .
The Bland-Altman plot was performed to confirm the agreement of individual sHAS-BLED to cHAS-BLED scores (Figure 3 ).
Patients with sHAS-BLED score of 3 or more had a history of bleeding for 68.75% compared with 67.39% in those with cHAS-BLED score of 3 or more.
| D ISCUSS I ON
To the best of our knowledge, this trial was the first study that has demonstrated sHAS-BLED score could be used in AF patients receiving warfarin. The sHAS-BLED and cHAS-BLED scores were comparable and they had a very strong correlation. 17 There was also F I G U R E 1 The distribution of patients in SAMe-TT 2 R 2 score TA B L E 2 Comparison between sHAS-BLED and cHAS-BLED score sHAS-BLED score cHAS-BLED score P-value Mean ± SD 2.27 ± 0.92 2.19 ± 0.97 .08
Abbreviations: cHAS-BLED, conventional HAS-BLED; SD, standard deviation; sHAS-BLED, simplified HAS-BLED. Previous trials showed the cHAS-BLED score could be used to predict bleeding events in AF patients. 15 Labile INR in cHAS-BLED was defined as TTR < 60% in those trials including several standard clinical practice guidelines. 16, 18 Previous clinical trials have demonstrated that poor TTR is associated with adverse events including thromboembolism, bleeding, and/or mortality. 7, 8 To date, well-controlled VKAs has been used TTR more than 70% as reflect in recommendations of recent clinical practice guidelines. 2, 3, 18 This trial defined the labile INR by using TTR < 70% as a substitute for those < 60% in cHAS-BLED score because of SAMe-TT 2 R 2 score was proved to predict labile INR < 65%-70% in previous trials. [9] [10] [11] [12] [13] Nevertheless, labile INR in cHAS-BLED score in this trial may be different from those in previous HAS-BLED score trials.
F I G U R E 2 Relationship between sHAS-BLED and cHAS-BLED scores
The sHAS-BLED score could be used to improve the easier Nevertheless, patients with sHAS-BLED score of 3 or more had a history of bleeding comparable to those with cHAS-BLED score of 3 or more. However, larger clinical trial will be needed to prove whether sHAS-BLED can predict bleeding risk in the future. Finally, this study was a retrospective study and there may be some missing data. However, this trial was the first study that has demonstrated sHAS-BLED score was more simplified and comfortable to use in clinical practice.
| CON CLUS IONS
The sHAS-BLED by using SAMe-TT 2 R 2 score of 3 or more as a substitute for labile INR was not statistically significantly different compared with cHAS-BLED score and can be used in clinical practice.
However, larger clinical trial will be needed to prove whether sHAS-BLED can predict bleeding risk in the future.
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